Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of carePOMPANO BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced top-line ...

公司概况 - 公司是一家盈利性医疗技术公司，专注于先进伤口护理领域 [2] - 公司核心专有技术为BioREtain，用于处理基于胎盘组织的移植物 [2][3] 技术与应用 - 核心技术BioREtain处理的移植物用于治疗糖尿病足溃疡、压力性溃疡和静脉性腿部溃疡 [3] - 目标患者群体约为700万医疗保险受益人 [3] 市场规模 - 先进伤口护理领域的整体市场规模约为113亿美元 [3]